Nayak RC, et al. (2022) Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis. Nat Commun 13, 3056 35650206

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S473-p - Akt1 (mouse) ▲

Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  B lymphocyte Cellular systems studied:  primary cells Species studied:  human, mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes VAV3 (human) decrease VAV3 KO increases MK-2206 VAV3 (human) augment treatment-induced decrease Downstream Regulation Effect of modification (function):  enzymatic activity, induced, phosphorylation Effect of modification (process):  carcinogenesis, inhibited, cell cycle regulation, cell growth, inhibited, transcription, induced Comments:  induces BMI phosphorylation

S314-p - BMI1 (mouse) ▲

Modsite: ASRPRKssLNGSSAT SwissProt Entrez-Gene Orthologous residues BMI1 (human): S316‑p, BMI1 (mouse): S314‑p, BMI1 (rat): S314‑p Characterization Methods used to characterize site in vivo:  mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  B lymphocyte Cellular systems studied:  primary cells Species studied:  human, mouse Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE Akt1 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes VAV3 (human) decrease VAV3 KO increases MK-2206 VAV3 (human) augment treatment-induced decrease Downstream Regulation Effect of modification (process):  carcinogenesis, inhibited, cell cycle regulation, cell growth, inhibited, transcription, induced

Y173-p - VAV3 (mouse) ▲

Modsite: EDEGGEVyEDLMKAE SwissProt Entrez-Gene Orthologous residues VAV3 (human): Y173‑p, VAV3 iso4 (human): Y173‑p, VAV3 (mouse): Y173‑p, VAV3 (rat): Y173‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  B lymphocyte Cellular systems studied:  primary cells Species studied:  human, mouse Downstream Regulation Effect of modification (function):  activity, induced